Clinical Trials Logo

Metastatic Nasopharyngeal Cancer clinical trials

View clinical trials related to Metastatic Nasopharyngeal Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05385926 Recruiting - Clinical trials for Metastatic Nasopharyngeal Cancer

Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

Start date: May 5, 2022
Phase: Phase 2
Study type: Interventional

Incidences of de novo metastatic nasopharyngeal carcinoma range from 6% to 8% at the time of presentation. For the initial diagnosis of metastatic NPC, PD-1 plus chemotherapy yields a satisfactory outcome with1year PFS of 40%. Previous study demonstrated the benefit of adding radiotherapy to chemotherapy in metastatic NPC, however there is no evidence whether radiotherapy can further improve PFS based on chemotherapy plus PD-1 . The purpose of this study is to evaluate the safety and effectiveness of first-line immunochemotherapy combined with radiotherapy for initial diagnosed metastatic NPC.

NCT ID: NCT05198479 Recruiting - Clinical trials for Metastatic Nasopharyngeal Cancer

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

SG-AAA-II-01
Start date: May 5, 2023
Phase: Phase 2
Study type: Interventional

This study is the first phase II study of 177Lu-DOTA0-Tyr3-Octreotate in metastatic NPC. Patients whom have failed 2 or more lines of therapy or exhausted standard therapy and are avid on 68Ga-DOTATATE imaging will be eligible to receive up to 4 cycles of 177Lu-DOTA0-Tyr3-Octreotate. The primary outcome will be progression free survival at 6 months.